As the COVID-19 pandemic continues its global impact into 2021, what we have learned in 2020 is being leveraged to optimize patient care and prioritize precious resources. In this webinar, we continue the conversation from Part 1 of this topic, presenting additional data from a study using flow cytometry data to explore the role of T-cell subtypes as a surrogate biomarker to elucidate risk, disease severity, and clinical outcomes for patients with COVID-19. The speakers are experts and global leaders in cytometry and infectious disease who have been working on the frontlines of the COVID-19 outbreaks in the United States, United Kingdom, and Europe. They will provide concrete examples of how flow cytometry has been harnessed to provide key laboratory evidence that can help clinicians prioritize limited resources in the fight against SARS-CoV-2 and COVID-19.
During the webinar, the speakers will:
- Describe how immune profiling using flow cytometry is revealing surrogate biomarkers for clinical outcomes of COVID-19
- Provide examples of how results at the bench might be translated to the clinic to impact patient care
- Outline how deeper immune profiling of lymphocyte subsets might inform better patient treatment in the future
- Answer your questions during the live broadcast.
You can also watch part 1 of this series.
This webinar will last for approximately 60 minutes.